Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Adam Boynton"'
Autor:
Sangita Pal, Adam Boynton, Ryan Johnston, Naomi Currimjee, Kenin Qian, Mehdi Touat, Charlotte Bellamy, Patricia Ho, David Root, Nicole Persky, Amy Goodale, Jim Berstler, Lisa Miller, Alex Guletsky, Marta Cortes-Cros, Keith Ligon, Rameen Beroukhim, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:vii231-vii232
Approximately 25% of recurrent gliomas exhibit hypermutation, which is most often acquired in chemotherapy sensitive gliomas post-treatment with standard of care alkylating agent temozolomide, Intriguingly, nearly all of these recurrent hypermutant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a73565ea4bd1b91fd607cd087ac329f4
https://doi.org/10.1093/neuonc/noac209.893
https://doi.org/10.1093/neuonc/noac209.893
Autor:
Florence Coulet, Jill S. Barnholtz-Sloan, Marc Sanson, Adam Boynton, Aniket Shetty, Yvonne Y. Li, Tracy T. Batchelor, Marine Giry, Garrett M. Frampton, Alexandre Carpentier, Peter J. Park, Franck Bielle, Eudocia Q. Lee, Khê Hoang-Xuan, Jean-Yves Delattre, Leon Taquet, Philippe Cornu, Erell Guillerm, Andrew D. Cherniack, Liam F. Spurr, Robert E. Jones, Mehdi Touat, Rameen Beroukhim, Patrick Y. Wen, J. Bryan Iorgulescu, David Meredith, Kristine Pelton, Caroline Dehais, Radwa Sharaf, Sandro Santagata, Alex Duval, Kenin Qian, Nadia Younan, Florence Laigle-Donadey, Patricia Ho, J Ricardo McFaline-Figueroa, Juliana Bonardi, Mary Jane Lim-Fat, David A. Reardon, Capucine Baldini, Naomi Currimjee, Shakti H. Ramkissoon, Caroline Houillier, Katie Pricola Fehnel, Seth Malinowski, Dimitri Psimaras, Cristina Birzu, Charlotte Bellamy, Isidro Cortes-Ciriano, Keith L. Ligon, Jack Geduldig, Karima Mokhtari, Maite Verreault, Lee A. Albacker, Pratiti Bandopadhayay, Bertrand Mathon, Susan N. Chi, E. Antonio Chiocca, Agusti Alentorn, Dean Pavlick, Frank Dubois, Sangita Pal, Samy Ammari, Brian M. Alexander, Arnab Chakravarti, Azra H. Ligon, Sanda Alexandrescu, Ahmed Idbaih, Frédéric Beuvon, Lakshmi Nayak, Laurent Capelle, Aurélien Marabelle, Daphne A. Haas-Kogan, Raymond Y. Huang, Craig L. Bohrson, Wenya Linda Bi, Ruben Ferrer-Luna, Kin-Hoe Chow
Publikováno v:
Nature
A high tumour mutational burden (hypermutation) is observed in some gliomas1–5; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336eef6ce9a5c79711dafc9d15cebb54
https://doi.org/10.1038/s41586-020-2209-9
https://doi.org/10.1038/s41586-020-2209-9
Autor:
Adam Boynton, Leslie Lupien, Pratiti Bandopadhayay, Gabrielle Gionet, David E. Root, Rushil Kumbhani, Amy Goodale
Publikováno v:
Neuro Oncol
MYC-driven medulloblastomas are a particularly devastating group of pediatric brain tumors that exhibit resistance and continued progression despite standard of care treatments. Our preclinical work identified BET-bromodomain inhibitors as a potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb6523e0199cbbf34e30af2f044bd2e1
https://europepmc.org/articles/PMC8598678/
https://europepmc.org/articles/PMC8598678/
Autor:
Leslie Lupien, Adam Boynton, Madison Chacon, Rushil Kumbhani, Gabrielle Gionet, Amy Goodale, David Root, Hasmik Keshishian, Margaret Robinson, Steven Carr, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:i123-i123
MYC-driven medulloblastomas are a particularly devastating group of pediatric brain tumors that exhibit resistance and continued progression despite standard of care treatments. Our preclinical work identified BET-bromodomain inhibitors as a potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9c6f9df5d83e7af6232ff75f570ef9
https://doi.org/10.1093/neuonc/noac079.447
https://doi.org/10.1093/neuonc/noac079.447
Autor:
Adam Boynton, Leslie Lupien, Rushil Kumbhani, Gabrielle Gionet, Madison Chacon, Amy Goodale, David Root, Hasmik Keshishian, Margaret Robinson, Steven Carr, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:i126-i126
BET-bromodomain inhibition (BETi) is a promising therapeutic strategy to target MYC-driven cancers, including Group 3 medulloblastoma, a deadly childhood brain tumor. We have shown that BET inhibitors exhibit preclinical efficacy against MYC¬-amplif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591a3344becc33109b42b430a229a90f
https://doi.org/10.1093/neuonc/noac079.459
https://doi.org/10.1093/neuonc/noac079.459
Autor:
Bryan Iorgulescu, Mehdi Touat, Andrew D. Cherniack, Agusti Alentorn, David A. Reardon, Caroline Dehais, Rameen Beroukhim, Capucine Baldini, Khê Hoang-Xuan, Karima Mokhtari, Aurélien Marabelle, Alexandre Carpentier, Raymond Y. Huang, Alex Duval, Marc Sanson, Sangita Pal, Adam Boynton, Maite Verreault, Franck Bielle, Azra H. Ligon, Brian M. Alexander, Pratiti Bandopadhayay, Ennio Antonio Chiocca, David Meredith, Frédéric Beuvon, Erell Guillerm, Patrick Y. Wen, Lakshmi Nayak, Nadia Younan, Sandro Santagata, Florence Laigle-Donadey, Daphne A. Haas-Kogan, Ruben Ferrer-Luna, Florence Coulet, Jack Geduldig, Eudocia Q. Lee, Susan N. Chi, Sanda Alexandrescu, Jean-Yves Delattre, Wenya Bi, Christina Birzu, Samy Ammari, Ahmed Idbaih, Keith L. Ligon, Bertrand Mathon, Philippe Cornu, Liam F. Spurr, Yvonne Y. Li, Caroline Houiller, Charlotte Bellamy
Publikováno v:
Neuro Oncol
BACKGROUND Hypermutation is an emerging biomarker for predicting response to immunotherapy in cancer patients, however its clinical value in gliomas is not established. We sought to assess the determinants of hypermutation in gliomas, and its value f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82fc8a1adb5f5a8cd313903782f2363a
https://europepmc.org/articles/PMC6847135/
https://europepmc.org/articles/PMC6847135/
Autor:
Karima Mokhtari, Yi Li, Shannon Block, Mehdi Touat, Florence Coulet, A. Idbaih, Alex Duval, Pratiti Bandopadhayay, M. Sanson, Patrick Y. Wen, Antoine F. Carpentier, Marine Giry, J.-Y. Delattre, Franck Bielle, Frédéric Beuvon, Erell Guillerm, Liam F. Spurr, Raymond Y. Huang, Aurélien Marabelle, B Iorglescu, Adam Boynton, Jack Geduldig, Khê Hoang-Xuan, M Lim Fat, Andrew D. Cherniack, Rameen Beroukhim, Keith L. Ligon, Sandro Santagata, Cristina Birzu, David A. Reardon
Publikováno v:
Neuro Oncol
BACKGROUND Among patients with glioma, little is known about the clinical significance of hypermutation. We sought to define the determinants of hypermutation in gliomas, and to assess the value of this biomarker for predicting response to standard o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24f5fa6c78ea9c5d54c8075a0bc478be
https://europepmc.org/articles/PMC6795177/
https://europepmc.org/articles/PMC6795177/
Autor:
Mehdi Touat, Kenin Qian, Patricia Ho, Sangita Pal, Jim Berstler, Pratiti Bandopadhayay, Adam Boynton, Charlotte Bellamy, Naomi Currimjee, Keith L. Ligon, Rameen Beroukhim
Publikováno v:
Neuro-Oncology
INTRODUCTION We have observed that approximately 26% of recurrent gliomas acquire hypermutation following treatment with temozolomide (TMZ). Intriguingly, 91% of these tumors harbor mutations in mismatch repair (MMR) genes. Strategies to target MMR-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a59da50d99018b7f37bd79fa2ebf7fe8
http://europepmc.org/articles/PMC7715373
http://europepmc.org/articles/PMC7715373
Autor:
Brian M. Alexander, Shakti H. Ramkissoon, Mehdi Touat, Seth Malinowski, Arnab Chakravarti, Philippe Cornu, Andrew D. Cherniack, Agusti Alentorn, Karima Mokhtari, Caroline Dehais, Jack Geduldig, Kenin Qian, Florence Laigle-Donadey, Maite Verreault, Kin-Hoe Chow, Jill S. Barnholtz-Sloan, Marc Sanson, Adam Boynton, Ahmed Idbaih, Dimitri Psimaras, Bertrand Mathon, Aniket Shetty, Sangita Pal, Yvonne Y. Li, Franck Bielle, Caroline Houillier, Laurent Capelle, Garrett M. Frampton, Craig L. Bohrson, Samy Ammari, Frank Dubois, David A. Reardon, Aurélien Marabelle, Liam F. Spurr, Mary J. Lim-Fat, Isidro Cortes-Ciriano, Erell Guillerm, Alexandre Carpentier, Pratiti Bandopadhayay, Frédéric Beuvon, Charlotte Bellamy, Kristine Pelton, Bryan Iorgulescu, Wenya Linda Bi, Peter J. Park, Patrick Y. Wen, Rameen Beroukhim, Naomi Currimjee, Keith L. Ligon
Publikováno v:
Cancer Research. 80:5705-5705
High tumor mutational burden (hypermutation) is observed in some gliomas; however, its mechanisms of development and whether it predicts immunotherapy response are poorly understood. Here, we comprehensively analyze the molecular determinants of muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f22321c78f0f95741e862f9f7ac8ae9a
https://doi.org/10.1158/1538-7445.am2020-5705
https://doi.org/10.1158/1538-7445.am2020-5705